The Latest

  • COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer
COUR Pharmaceuticals Logo

COUR Pharmaceuticals

  • Our Company
    • Leadership
    • Board of Directors
    • Advisors
    • Partners
    • Contact
  • Our Technology
    • Pipeline
  • Our Clinical Trials
    • CNP-106 Myasthenia Gravis
  • Publications & Media
    • Press Releases
    • Publications
  • Careers

Board of Directors

Dannielle Appelhans
Dannielle Appelhans Featured

Dannielle Appelhans

President & CEO

Robert F. Carey
Robert F. Carey Featured

Robert F. Carey

Lead Independent Director

Chris Dimitropoulos
Chris Dimitropoulos Featured

Chris Dimitropoulos

Alpha Wave Global, LP
Managing Director

Simon Greenwood
Simon Greenwood Featured

Simon Greenwood

Roche Venture Fund
Senior Investment Director

John J. Puisis
John J. Puisis Featured

John J. Puisis

Founder & Former President & CEO

Beni Rovinski, PHD
Beni Rovinski, PHD Featured

Beni Rovinski, PHD

Lumira Ventures
Managing Director

Tim Walbert
Tim Walbert Featured

Tim Walbert

Former Chairman, President and Chief Executive Officer, Horizon Therapeutics;
Sr. Advisor, Amgen

Footer

COUR Pharmaceuticals Logo
  • Our Company
  • Our Technology
  • Our Partners
  • Press
  • Careers

©

2025

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use

Back to Top